EVEROLIMUS vs GLEEVEC

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 16, 2026·How we rate

Possible drug interaction. EVEROLIMUS and GLEEVEC are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	EVEROLIMUS	GLEEVEC
Rating	70/100	70/100
Pharmacy pays	~$229.16 /30	~$25.80 /30
Type	RX	RX
Active ingredient	EVEROLIMUS	IMATINIB MESYLATE
Manufacturer	Biocon Pharma	Novartis
Dosage forms	Tablet	Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	Boxed warning	None
Half-life	about 30 hours (mean terminal elimination half-life)	—
Treats	—	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

everolimus gleevec

Rating

70/100

Pharmacy pays

~$229.16 /30

~$25.80 /30

Type

Active ingredient

EVEROLIMUS

IMATINIB MESYLATE

Manufacturer

Biocon Pharma

Novartis

Dosage forms

Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Half-life

about 30 hours (mean terminal elimination half-life)

—

Treats

—

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Frequently asked questions

Which is better-rated, Everolimus or Gleevec?

Everolimus and Gleevec are tied at 3.5 out of 5 by our independent rating.

Which is cheaper, Everolimus or Gleevec?

Gleevec costs pharmacies less to acquire — about $25.80 vs $229.16 for a 30-count supply, per the CMS NADAC survey. That gap is in the pharmacy's cost of goods, not necessarily in what you pay: your price is set afterwards by your insurer and the pharmacy.

What is the difference between Everolimus and Gleevec?

Everolimus contains Everolimus, while Gleevec contains Imatinib Mesylate — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.